A Single Ascending Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of LY3002815 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 12 Nov 2018
Price : $35 *
At a glance
- Drugs LY 3002815 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly
- 30 Oct 2018 Status changed from active, no longer recruiting to discontinued.
- 11 Sep 2018 Planned End Date changed from 1 Oct 2018 to 13 Oct 2018.
- 18 Aug 2017 Planned End Date changed from 1 Dec 2017 to 1 Oct 2018.